ARIA is the most common side effect of anti–amyloid-beta MAB treatment. MABs increase vascular permeability, which can result in inflammation and leakage of proteinaceous fluid and blood products, ...
Beta-amyloid plaques are considered a hallmark of Alzheimer’s disease, but they’re not the sole cause of the disease and its symptoms. Alzheimer’s is a complicated disease that experts are still ...
A recent study tests a new drug, gantenerumab on people with a genetically inherited form of Alzheimer’s disease. For people with this condition, dementia is almost inevitable. Gantenerumab helps ...
Early in Alzheimer’s disease, your brain can begin to change long before anyone notices a lost name or missed appointment. Toxic proteins quietly collect inside cells, support cells turn restless, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results